Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608204 | 0.85 | KDM1A (0.45) | DPP4GRIN1GRIN2BKDM1A | |
| SCHEMBL13608131 | 0.81 | BRD4 (0.41) | BRD4ATAD2TLR7KDM1A | |
| SCHEMBL13608172 | 0.80 | BRD4 (0.41) | BRD4ATAD2TLR7KDM1A | |
| SCHEMBL13608202 | 0.76 | KDM1A (0.40) | DPP4GRIN1GRIN2BBRD4ATAD2 | |
| SCHEMBL13608139 | 0.75 | KDM1A (0.44) | BRD4ATAD2TLR7KDM1A | |
| SCHEMBL13620417 | 0.75 | KDM1A (0.46) | GRIN1GRIN2BBRD4ATAD2KDM1A | |
| SCHEMBL12399644 | 0.75 | BRD4 (0.42) | BRD4ATAD2KDM1ACYP3A4 | |
| SCHEMBL13608122 | 0.75 | BRD4 (0.42) | BRD4ATAD2KDM1ACYP3A4 | |
| SCHEMBL13620419 | 0.75 | GRIN1 (0.48) | DPP4GRIN1GRIN2B | |
| SCHEMBL13620050 | 0.72 | KDM1A (0.49) | BRD4ATAD2KDM1ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | DPP4 3354/4885GRIN1 554/4885GRIN2B 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.